Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02524951 · ClinicalTrials.gov registry record · Phase 1
Safety and Tolerability of MSI-1436C in Metastatic Breast Cancer
A Phase 1 study, sponsored by Northwell Health.
- Terminated
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT02524951 is a Phase 1 study that was terminated before completion, run by Northwell Health. The registered enrollment target is 5 participants.
The verdict
NCT02524951, a Phase 1 study, was terminated before completion, sponsored by Northwell Health.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
This is a Phase I, open-label, dose escalation study. MSI-1436 will be administered as a single intravenous infusion twice a week for 3 weeks on a 4-week cycle.
Interventions
- DRUG MSI-1436C
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2016-04 |
| Est. Completion | 2018-05-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02524951
The ClinicalTrials.gov registry entry for NCT02524951 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwell Health, which has 370 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MSI-1436C is the first listed.
NCT02524951 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02524951 about?
NCT02524951 is a clinical study titled "Safety and Tolerability of MSI-1436C in Metastatic Breast Cancer". This is a Phase I, open-label, dose escalation study. MSI-1436 will be administered as a single intravenous infusion twice a week for 3 weeks on a 4-week cycle.
What is the current status of trial NCT02524951?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2016-04. Estimated completion is 2018-05-14.
What interventions are being tested in trial NCT02524951?
The interventions under investigation include: MSI-1436C (DRUG).
Who is sponsoring clinical trial NCT02524951?
This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.